Oscar Health raises FY26 earnings guidance by $100 million
Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.
How this was made
The 30-second read
Why it matters
The guidance lift is a fresh, material disclosure that can be acted on immediately, offering a clear bullish catalyst.
Market read
Guidance upgrade is likely to drive OSCR higher in the short term and may influence peer valuations.
What to watch
Potential regulatory changes or unexpected claim spikes could offset the projected cost savings.
Background
Oscar Health announced its FY26 guidance update ahead of its Investor Day, highlighting tighter loss ratios and higher operating earnings.
Ticker impact
Oscar Health raised FY26 earnings from operations guidance by $100 million and tightened its medical loss ratio outlook.
upward pressure, potential 3‑5% move in the near term
The $100 M earnings lift and 50 bp MLR improvement are material for a mid‑cap health insurer and were disclosed for the first time.
Market effects
May prompt re‑rating of other health insurers as cost‑control gains become a focus.
Positive for U.S. health‑insurance sector, limited broader market effect.
Low; primarily U.S. equity impact.
Counterpoint
If the MLR improvement proves unsustainable, the guidance could be revised down, leading to a pull‑back.
Key entities
- companyOscar Health, Inc.
U.S. health‑insurance provider (ticker OSCR).
- executiveScott Blackley
Chief Financial Officer of Oscar Health who commented on the guidance.
